Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

9.70
-0.1200-1.22%
Post-market: 9.700.0015+0.02%16:20 EDT
Volume:2.76M
Turnover:26.56M
Market Cap:2.48B
PE:-6.44
High:9.72
Open:9.72
Low:9.46
Close:9.82
52wk High:11.22
52wk Low:6.00
Shares:255.54M
Float Shares:222.00M
Volume Ratio:1.21
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5054
EPS(LYR):1.21
ROE:587.33%
ROA:52.86%
PB:-5.46
PE(LYR):8.02

Loading ...

BioCryst Pharmaceuticals - Expects Additional Costs for Discovery Center Closure; Analysis Ongoing - SEC Filing

THOMSON REUTERS
·
Aug 04

BioCryst Pharmaceuticals - Estimates $6.2-$7.50 Mln in One-Time Expenses for Termination Benefits, $5.3-$6.60 Mln Cash - SEC Filing

THOMSON REUTERS
·
Aug 04

BioCryst Amends 8-K, Estimates $6.2 Million-$7.5 Million in One-Time Severance Costs for Discovery Shutdown Plan

Reuters
·
Aug 04

BioCryst Pharmaceuticals (BCRX) Faces A Valuation Test, Is The Undervalued Case Convincing?

Simply Wall St.
·
Aug 04

Earning Preview: Biocryst Pharmaceuticals Q2 revenue is expected to increase by 21.89%, and institutional views are cautiously optimistic

Earnings Agent
·
Jul 29

Biocryst to Report Q2 2026 Results, Host Conference Call and Webcast

Reuters
·
Jul 22

Biocryst Names David Jenkins Chief Scientific Officer

Reuters
·
Jul 15

Biocryst Appoints David W. Jenkins as Chief Scientific Officer

THOMSON REUTERS
·
Jul 15

BioCryst (BCRX) Receives a Buy from Wedbush

TIPRANKS
·
Jul 13

Biocryst Pharmaceuticals Price Target Announced at $12.00/share by JP Morgan

Dow Jones
·
Jul 13

J.P. Morgan Initiates a Hold Rating on BioCryst (BCRX)

TIPRANKS
·
Jul 13

Is BioCryst (BCRX) Trading Internal Discovery for a More Durable Rare-Disease Innovation Model?

Simply Wall St.
·
Jul 09

Biocryst Pharmaceuticals is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 07

Eupraxia Pharma Adds Robert Bazemore, Amy Pott, Helen Thackray to Board

Reuters
·
Jul 07

Kioxia Ships Next-gen Memory Samples as AI Boom Fuels Dramatic Comeback

Reuters
·
Jul 03

Biocryst Grants New Hires Stock Options for 33,950 Shares at $9.65 Each

Reuters
·
Jul 02

Biocryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 02

Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Zymeworks (ZYME)

TIPRANKS
·
Jun 30

Biocryst Pharmaceuticals is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Jun 30

Cantor Fitzgerald Sticks to Its Buy Rating for BioCryst (BCRX)

TIPRANKS
·
Jun 30